The global Dermatological Drugs market size was estimated at USD 17.5 billion in 2021 and is expected to surpass around USD 37.9 billion by 2030 and poised to grow at a compound annual growth rate (CAGR) of 12.1% during the forecast period 2022 to 2030.
Key Takeaways:
- By Indication, the U.S. Dermatological Drugs market was valued at USD 4.7 Billion in 2021 and expected to witness growth at a CAGR of 10.1% from 2022 to 2030.
- The psoriasis segment dominated the market in 2021 with a revenue share of over 35.4%. The reason is that psoriasis affects all ages but is most prevalent in adults and contributes to dermatology drug revenue globally
- North America held the largest revenue share of more than 35.8% in 2021. The presence of well-established pharmaceutical vendors is one of the key factors supporting the market growth
- The acne segment is expected to expand with a CAGR of 11.5% from 2022 to 2030. Acne is a skin condition where dead skin and oil glands of skin glands are clogged, forming spots, pimples, and sometimes cysts
The key factors driving the global dermatological drug market are parasites, fungus, and other microorganisms living on the skin; bacteria trapped in skin pores and hair follicles; holding in various fluids; preventing dehydration, and increasing pollution levels. Moreover, growing awareness of skin diseases and increasing demand for rapid diagnosis, are also contributing to the growth of the dermatological drugs market. Increasing demand for innovative drugs & growing R&D investments in developing new drugs will contribute to the market revenue.
The global dermatological drugs market is expected to grow due to driving factors such as the availability of medical resources for detecting and treating skin diseases, nutritional deficiency due to unhealthy food habits, increasing awareness when it comes to lifestyle diseases, and increasing pollution levels, and lack of immunity in the population. Additionally, the rising per capita income and the increasing purchasing power are the driving forces in this market.
The acne segment is expected to expand with a CAGR of 11.5% from 2022 to 2030. Acne is a skin condition where dead skin and oil glands of skin glands are clogged, forming spots, pimples, and sometimes cysts. Additionally, infected hair follicles cause acne, which starts from the skin’s pores. Acne causes bumps on the face, shoulders, chest, and back in the form of pimples, blackheads, and whiteheads. Acne can be cured, and the appearance of the skin can be improved with effective treatment from dermatologists, contributing to the dermatological drug market.
North America held the largest revenue share of more than 35% in 2021. The U.S. is positively contributing to the growth of the regional market. The presence of well-established pharmaceutical vendors is one of the key factors supporting the market growth. This region is one of the promising regions to launch new technology in terms of healthcare infrastructure and advanced research and development activities that help innovate and produce the most appropriate drugs to cure cancer. It is observed that in the region, there is a rapid shift in the healthcare industry to consumer-driven from traditional treatment for providing diagnosis and provision-based health services. Additionally, ease of availability of drugs and reimbursement policies for the patient in the healthcare industry contributes to driving the market in the region.
Report Scope of the Dermatological Drugs Market
Indication Insights
The psoriasis segment dominated the market with a revenue share of more than 35.4% in 2021 and is expected to expand with the highest CAGR of 11.5% from 2022 to 2030. Psoriasis is caused by the immune system mistakenly attacking healthy skin cells. Psoriasis is not a contagious disease. The disease causes swollen fingers and toes, foot pain, lower back pain, nail changes, and eye inflammation. Psoriasis can be triggered by stress, skin injury, infections, some drugs, and heavy drinking. Psoriasis is found in all age groups but is majorly seen in adults and contributes to the global dermatology drug revenue.
The alopecia segment is likely to expand with the second-highest CAGR of 10.9% from 2022 to 2028. Alopecia caused due to the body’s immune system attacking hair follicles resulting in hair loss. Alopecia is an autoimmune disorder that results in hair coming out. Both men and women suffer from Alopecia due to an imbalance of hormones, hair care treatments, scalp infections, and possible side effects of some medications. Additionally, hereditary hair loss is the most common cause of hair loss globally. Citizens are careful about hair loss and visit hospitals for diagnosis. Hair loss requires ongoing treatments for a long period and contributes to the market growth rate.
Regional Insights
Asia Pacific is likely to expand at the highest CAGR of 12.8% from 2022 to 2030. Countries such as China and India, with the largest populations in the world, are expected to have many patients with skin diseases during the forecast period. Continuous improvement in the life science industry and health services and the awareness of skin diseases and their treatment are factors contributing to the highest growth of this market. Moreover, increasing incomes and the purchasing power of citizens are witnessing a significant growth rate in this market.
Europe held the second-largest revenue share of more than 30.7% in 2021 and is expected to continue with a growth of 11% during the forecast period. Factors such as increasing large investment in the healthcare sector, greater prevalence of healthcare insurance among the masses, and supportive regulatory frameworks of the pharmaceutical industry in this region are attributed to the market revenue generation.
Some of the prominent players in the Dermatological Drugs Market include:
- Novartis AG
- Amgen Inc
- AbbVie Inc
- Johnson & Johnson
- Leo Pharma A/S
- Eli Lilly and Company
- GlaxoSmithKline Plc
- AstraZeneca plc
- Pfizer Inc
- Merck KGaA
Segments Covered in the Report
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Dermatological Drugs market
- Acne
- Psoriasis
- Rosacea
- Alopecia
- Others
By Geography
North America
Europe
- Germany
- France
- United Kingdom
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- Southeast Asia
- Rest of Asia Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC
- North Africa
- South Africa
- Rest of Middle East & Africa
Key Points Covered in Dermatological Drugs Market Study:
- Growth of Dermatological Drugs in 2022
- Market Estimates and Forecasts (2017-2030)
- Brand Share and Market Share Analysis
- Key Drivers and Restraints Shaping Market Growth
- Segment-wise, Country-wise, and Region-wise Analysis
- Competition Mapping and Benchmarking
- Recommendation on Key Winning Strategies
- COVID-19 Impact on Demand for Dermatological Drugs and How to Navigate
- Key Product Innovations and Regulatory Climate
- Dermatological Drugs Consumption Analysis
- Dermatological Drugs Production Analysis
- Dermatological Drugs and Management
Request Customization
Get a Sample
Get a Sample
Request Customization